BioProject

India accounts for 20% of the global retinoblastoma (RB) burden. Existing data is sparse on RB1 gene germline mutations and its influence on clinical decisions is minimally explored. More...

India accounts for 20% of the global retinoblastoma (RB) burden. Existing data is sparse on RB1 gene germline mutations and its influence on clinical decisions is minimally explored. Fifty children with RB were screened for germline RB1 gene mutations through next-generation sequencing. The influence of the germline mutations on the clinical management and severity. Less...